Andrew S. Moore

Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias

J. Blagg, A. Moore, A. Pearson, 2010, Leukemia.

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia

G. Acton, A. Boddy, P. Kearns, 2017, Pediatric blood & cancer.